Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBITDA (2019 - 2025)

Pulmonx (LUNG) has disclosed EBITDA for 7 consecutive years, with -$14.4 million as the latest value for Q3 2025.

  • Quarterly EBITDA fell 5.68% to -$14.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$57.0 million through Sep 2025, down 0.94% year-over-year, with the annual reading at -$56.9 million for FY2024, 4.78% up from the prior year.
  • EBITDA for Q3 2025 was -$14.4 million at Pulmonx, up from -$14.7 million in the prior quarter.
  • The five-year high for EBITDA was -$10.1 million in Q3 2021, with the low at -$16.1 million in Q1 2022.
  • Average EBITDA over 5 years is -$14.1 million, with a median of -$14.4 million recorded in 2025.
  • The sharpest move saw EBITDA crashed 164.33% in 2021, then increased 8.91% in 2024.
  • Over 5 years, EBITDA stood at -$12.8 million in 2021, then dropped by 9.87% to -$14.1 million in 2022, then rose by 6.47% to -$13.2 million in 2023, then dropped by 3.06% to -$13.6 million in 2024, then fell by 5.58% to -$14.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$14.4 million, -$14.7 million, and -$14.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.